ArticleInternational journal of molecular sciences2020
The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer.
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Molecular Prognostic Factors in Uterine Serous Carcinomas: A Systematic Review.Current oncology (Toronto, Ont.) · 2025Pooled it
- Cannabinoids in Cancer: Molecular Mechanisms of Tumor Cell Death and Translational Opportunities.Biomolecules · 2026Review
- Medical Cannabis and the Hallmarks of Cancer: A Critical Narrative Review.International journal of molecular sciences · 2026Review
- Antitumor Activity of Cannabinoids and Their Interaction with Chemotherapy: A Systematic Review and Meta-Analysis of Preclinical Evidence.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Review
- Cannabidiol-Induced Tumor Cell Death: Molecular Mechanisms and Translational Perspectives in Cancer Therapy.Drug design, development and therapy · 2026Review
- Cannabinoids in oncology: pharmacology, clinical applications, and translational perspectives.Frontiers in pharmacology · 2026Review
- Calcium Homeostasis Machinery in the Human Uterus-A Potential Therapeutic Target in Endometrial Cancer.International journal of molecular sciences · 2025Review
- The Function and Clinical Significance of TRPV2 in Human Colon Cancer.Annals of surgical oncology · 2025Article
- Expression, Distribution and Function of the Transient Receptor Potential Vanilloid Type 1 (TRPV1) in Endometrial Cancer.International journal of molecular sciences · 2025Article
- Mechanisms of Cell Death Induced by Cannabidiol Against Tumor Cells: A Review of Preclinical Studies.Plants (Basel, Switzerland) · 2025Review
- Utilization of Cannabidiol in Post-Organ-Transplant Care.International journal of molecular sciences · 2025Review
- Review
- Micro- and Macronutrients in Endometrial Cancer-From Metallomic Analysis to Improvements in Treatment Strategies.International journal of molecular sciences · 2024Review
- Cannabigerol Induces Autophagic Cell Death by Inhibiting EGFR-RAS Pathways in Human Pancreatic Ductal Adenocarcinoma Cell Lines.International journal of molecular sciences · 2024Article
- Targeting Nrf2 Signaling Pathway in Cancer Prevention and Treatment: The Role of Cannabis Compounds.Antioxidants (Basel, Switzerland) · 2023Review
- Ion Channels and Personalized Medicine in Gynecological Cancers.Pharmaceuticals (Basel, Switzerland) · 2023Review
- "ThermoTRP" Channel Expression in Cancers: Implications for Diagnosis and Prognosis (Practical Approach by a Pathologist).International journal of molecular sciences · 2023Review
- ANXA6/TRPV2 axis promotes lymphatic metastasis in head and neck squamous cell carcinoma by inducing autophagy.Experimental hematology & oncology · 2023Article
- Drug-Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several studies support, both in vitro and in vivo, the anti-cancer effects of cannabidiol (CBD), a transient receptor potential vanilloid 2 (TRPV2) ligand. TRPV2, often dysregulated in tumors, is associated with altered cell proliferation and aggressiveness. Endometrial cancer (EC) is historically divided in type I endometrioid EC and type II non-endometrioid EC, associated with poor prognosis. Treatment options with chemotherapy and combinations with radiation showed only limited efficacy. Since no data are reported concerning TRPV2 expression as well as CBD potential effects in EC, the aim of this study was to evaluate the expression of TRPV2 in biopsies and cell lines as well as the effects of CBD in in vitro models. Overall survival (OS), progression-free survival (PFS), cell viability, migration, and chemo-resistance have been evaluated. Results show that TRPV2 expression increased with the malignancy of the cancer tissue and correlated with shorter PFS (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.